| Drug Name |
Glycopyrronium |
| Drug ID |
BADD_D02432 |
| Description |
Glycopyrronium, also known as NVA237 or glycopyrrolate, is a racemic mixture of two enantiomers.[L33110] They are both quaternary ammonium compounds and long acting muscarinic antagonists.[L33110] It is one of the most commonly prescribed anticholinergic medications.[A233535,A233540] Early research into glycopyrronium use was for its indication as an adjunct therapy in the treatment of peptic ulcers.[A233570,L33090] Later research, taking advantage of the systemic distribution of muscarinic receptors through the body, found that glycopyrronium could also be used for reducing sweat gland,[L4755] oral,[L33140] airway, and gastric secretions;[L33120] as well as reducing cardiac inhibitory reflexes;[L33120] and reducing bronchoconstriction in COPD.[L33105] Glycopyrronium is commonly prescribed as a first line treatment for a wide variety indications and is considered to have a wider therapeutic window than [tiotropium].[A233565]
Glycopyrronium was originally granted FDA approval on 11 August 1961.[L33090] |
| Indications and Usage |
For use as a preoperative antimuscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions, to reduce the volume and free acidity of gastric secretions and to block cardiac vagal inhibitory reflexes during induction of anesthesia and intubation. Also used to treat chronic obstructive pulmonary disease (COPD). |
| Marketing Status |
Not Available |
| ATC Code |
D11AA01 |
| DrugBank ID |
DB00986
|
| KEGG ID |
D10938
|
| MeSH ID |
D006024
|
| PubChem ID |
9933193
|
| TTD Drug ID |
D0M0AM
|
| NDC Product Code |
69489-411; 70428-011 |
| Synonyms |
Glycopyrrolate | Glycopyrronium Bromide | Bromide, Glycopyrronium | Pyrrolidinium, 3-((cyclopentylhydroxyphenylacetyl)oxy)-1,1-dimethyl-, bromide | Glycopyrronium | NVA237 | NVA 237 | NVA-237 |
